⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 1 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade

Brian M. Olson Kiranj Chaudagar Riyue Bao Sweta Sharma Saha Christina Hong Marguerite Li Srikrishnan Rameshbabu Raymond Chen Alison Thomas Akash Patnaik

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Enrichment of Rb1 or CDKN2A loss in non-T cell-inflamed primary prostate cancer and across multiple primary tumor histologies

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Olson et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db6435875224a6 https://doi.org/10.1158/1535-7163.27035878

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024
2Supplementary Figure 2 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024
3Supplementary Figure 2 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024
4Supplementary Figure 11 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024
5Supplementary Figure 11 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024

Supplementary Figure 4 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024
Supplementary Figure 4 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024
Supplementary Figure 9 from BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade2024